

HEALTH AND SAFETY DATA SHEET

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND COMPANY

COMPANY ADDRESS:	PRODUCT NAME:	ISSUE DATE: 25 November 2015
Dechra Pharmaceuticals PLC		
24 Cheshire Avenue	ZYCORTAL® SUSPENSION	PHYSICAL FORM:
Cheshire Business Park Lostock Gralam	(desoxycorticosterone pivalate injectable	Suspension for injection

Cheshire Business Park Lostock Gralam Northwich CW9 7UA UK

Tel: +44 (0) 1606 814730 Fax: +44 (0) 1606 814731

US Technical Support: (866) 933-2472

NADA 141-444

PRODUCT TYPE: Rx;
Mineralocorticoid Hormone

CONTAINER:

Type I glass vial (containing 4ml) with a coated chlorobutyl rubber stopper and aluminium seal with a plastic flip-off cap.

2. HAZARDS IDENTIFICATION: May cause eye and skin irritation.

Product may cause pain and swelling at the injection site if accidentally self-administered. This product may cause adverse effects on male reproductive organs and, as a result, fertility. This product may cause adverse developmental effects on unborn children and neonates.

Pregnant and breast-feeding women should avoid

administration of the product.

3. COMPOSITION/INFORMATION ON ACTIVE INGREDIENTS

NAME	mg/ml	<u>HAZARD</u>
Desoxycorticosterone pivalate	25	May cause eye and skin irritation. May cause adverse effects on male reproductive organs and, as a result, fertility. May cause adverse developmental effects on unborn children and neonates. Pregnant and breast-feeding women should avoid administration of the product.

Version: 25 November 2015 Page 1 of 4



4. FIRST-AID MEASURES

EYE CONTACT: In case of accidental spillage onto eyes, wash the affected

area with water. If irritation occurs, seek medical advice immediately and show the package leaflet or the label to the

physician.

DERMAL CONTACT: In case of accidental spillage onto skin, wash the affected

area with water. If irritation occurs, seek medical advice immediately and show the package leaflet or the label to the

physician.

INGESTION: Remove material and flush mouth with water. Seek medical

attention: treatment is symptomatic and includes

replacement of fluid and electrolytes.

INHALATION: Not applicable.

ACCIDENTAL INJECTION: In case of accidental self-injection, seek medical advice

immediately and show the package leaflet or the label to the

physician.

EQUIPMENT AT WORKPLACE: Eye and skin washing facilities.

5. FIRE-FIGHTING MEASURES (BULK ACTIVE)

FLAMMABILITY: Not flammable.

SUITABLE EXTINGUISHERS:

Water spray, carbon dioxide, dry chemical and foam, as appropriate for surrounding fire and

materials.

EXPLOSIVE HAZARDS:

None known.

EXTINGUISHERS NOT TO BE USED:

None.

SPECIAL PROTECTIVE EQUIPMENT:

Evacuate area. Wear self-contained breathing

apparatus and protective clothing.

HAZARDOUS COMBUSTION PRODUCTS:

None

Version: 25 November 2015 Page 2 of 4



6. ACCIDENTAL RELEASE MEASURES

PERSONAL PROTECTION: Wear adequate eye protection and gloves.

SPILLAGE CLEAN-UP: Cover with an absorbent material, sweep up and place in an

approved chemical waste container. Wash the area with water containing a strong detergent, absorb with an absorbent material, sweep up and place in chemical container. Flush the area with water to remove any residue.

Avoid contamination of sewers and waterways.

7. HANDLING AND STORAGE

HANDLING: Handle with normal precautions as with any drug product.

STORAGE: Do not store above 30°C.

Do not freeze.

Keep out of the reach and sight of children.

8. EXPOSURE CONTROLS/PERSONAL

PROTECTION:

Not required under normal conditions of therapeutic administration and uses.

9. PHYSICAL AND CHEMICAL PROPERTIES OF PRODUCT

APPEARANCE (Zycortal Suspension): Opaque white suspension	MELTING POINT °C: Not applicable
SOLUBILITY IN WATER (DOCP): Not available	BOILING POINT ℃: Not available
MOLECULAR FORMULA (DOCP): C ₂₆ H ₃₆ O ₄	MOLECULAR MASS (DOCP): 414.58

10. STABILITY AND REACTIVITY: Stable under normal conditions and pressures.

Version: 25 November 2015 Page 3 of 4



11. TOXICOLOGICAL INFORMATION

EYE CONTACT: May cause irritation.

DERMAL CONTACT: May cause irritation.

INGESTION: Not known to cause any significant effects if ingested.

INHALATION: Not applicable.

ACCIDENTAL INJECTION: Product may cause pain and swelling at the injection site if

accidentally self-administered. This product may cause adverse effects on male reproductive organs and, as a

result, fertility. This product may cause adverse developmental effects on unborn children and neonates.

Pregnant and breast-feeding women should avoid

administration of the product.

12. ECOLOGICAL INFORMATION: Not expected to reach the environment in significant

amounts under normal circumstances.

13. DISPOSAL CONSIDERATIONS: Any unused veterinary medicinal product or waste materials

derived from such veterinary medicinal products should be

disposed of in accordance with local requirements.

14. TRANSPORT INFORMATION: Not regulated for domestic transport.

15. REGULATORY INFORMATION:

16. OTHER INFORMATION

Prepared by Dechra Pharmaceuticals PLC on the basis of the best available data. No representation is given that the information provided is complete in all respects.

Version: 25 November 2015 Page 4 of 4